Cantor Fitzgerald Weighs in on VNDA FY2025 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Vanda Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan forecasts that the biopharmaceutical company will post earnings of $1.30 per share for the year. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.32) per share.

Several other equities analysts have also recently commented on the stock. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research note on Monday. They set a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA opened at $4.42 on Thursday. Vanda Pharmaceuticals has a one year low of $3.46 and a one year high of $6.75. The stock’s fifty day moving average is $4.77 and its 200-day moving average is $5.02. The firm has a market capitalization of $257.73 million, a price-to-earnings ratio of -15.79 and a beta of 0.77.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Large investors have recently modified their holdings of the stock. ORG Wealth Partners LLC acquired a new stake in Vanda Pharmaceuticals during the 3rd quarter valued at $40,000. China Universal Asset Management Co. Ltd. lifted its stake in Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 4,374 shares in the last quarter. XTX Topco Ltd acquired a new stake in Vanda Pharmaceuticals during the 2nd quarter worth about $75,000. Intech Investment Management LLC purchased a new position in Vanda Pharmaceuticals during the 3rd quarter valued at about $84,000. Finally, SG Americas Securities LLC increased its holdings in shares of Vanda Pharmaceuticals by 88.5% in the 3rd quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 9,580 shares during the period. 88.14% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the sale, the director now directly owns 44,857 shares in the company, valued at approximately $231,910.69. This trade represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 8.90% of the stock is owned by corporate insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.